Follow us
A new test to help detect and monitor cancers
«We are bringing a new diagnostic solution to improve cancer detection and management throughout the patient care pathway.»
A simple and accessible test
Our R&D team found that hPG80 protein was present at high levels in the blood of patients with 16 different types of cancer, regardless of the stage of the disease.
Building on this groundbreaking French research, we developed a practical and cost-effective blood test: DxPG80.Lab.
DxPG80.Lab: a new device to lead the fight against cancer
Through a simple blood test, the DxPG80.Lab test detects the presence of hPG80, a biomarker associated with cancer activity.
Commercialized with CE marking
Easy
Rapid execution
(<3 hours)
Reliability
Affordable
CE-marked
hPG80 is detected in all cancers tested, including those for which no markers are available.
Tested on > 4,000 cancer patients and 1,200 healthy subjects.
Detected across all stages of 16 different types of cancer.
Proposing a more efficient support
A biomarker to support decision-making throughout the patient care pathway.
DxPG80.Lab provides valuable insights to help clinicians optimise patient care.
DETECTION
DIAGNOSIS
PROGNOSIS
TREATMENT
OUTCOME
PREDICTION
TREATMENT
MONITORING/
FOLLOW-UP
Despite significant progress over the last decade, the burden of cancer continues to rise.
20 million
new cases per year,
expected to rise to 31M in 2040.
> 50% late diagnosis
Over half of cancers in the US are diagnosed at stages III and IV.
79% vs 11%
79% vs 11% mortality
5-year cancer specific mortality when diagnosed late vs early stage.
Sources: WHO and Cancer Atlas
Strong unmet medical need
To detect cancer earlier and monitor treatment
with a low-cost blood test.
